The Origination Engine

Syndicated deal with c30% discount available, proven US Infrastructure Autonomous Vehicle Tech Firm

Offer by proven & exclusive manager for primary or secondary investment opportunity in holding of US industrial autonomous vehicle technology with blue chip contracts, return x5 anticipated, net of fees. No Management Fees and performance threshold for Carry.This technology, tested and proven by major US railroads among others, has secured a $30M contract for 50 vehicles, with significant pipeline subject to capacity. The investment is attractive due to discount, labour/ automation incentives, scalable technology, minimal regulatory/ union risks (private land), and strong interest from logistics and military sectors. The venture has substantial backing and is poised for rapid growth with further investments. INVEST AT YOUR OWN RISK: WE DO OUR HOMEWORK BUT DO NOT UNDERTAKE PROFESSIONAL DUE DILIGENCE. Further detail enclosed, with data room available following NDA and qualified expression of interest.

UK-based HNW with £50m RE portfolio needs lender for Jersey Commercial Property transaction

Professional RE investor with extensive Commercial and Residential property portfolio valued c£50m, sub-20% LTV and £3m income p.a., seeks Jersey-based bank lender to support an initial portfolio investment in Jersey, Channel Islands. Property is in St Helier, value £0.75m, will be subject of modernisation and refurbishment, and held in a company wholly-owned by the investor; will form the basis of a wider portfolio on the island over time. Source is regulated lending broker with existing professional relationship with the client.

Owner of UK manufacturer seeks lending line for acquisition opportunity, secured against commercial real estate

Successful UK business with £30m turnover and leader in manufacturing in sale of household materials with x25 acquisitions to date, seeks initial £1.2m funding line to acquire competitor (£2.5m cash price, £0.9m on balance sheet, putting in £1.3m cash and seeks £1.2m lend). Security against high quality industrial premises, wholly owned and current lend 15% LTV), and clear evidence of cashflow to service the loan. Currently banked with major high street bank and seeking alternative source of financing at competitive rate.

Novel LSE-listed pharmaceutical company focused on pain relief: raising £10m of CLN’s

Novel LSE-listed pharmaceutical company focused on pain relief: raising £10m of CLN’s and/ or equity to meet contractual commitments in UK/ EU and target US dual IPO in next 12~18 months. Expression of interest for £5m CLN paying 10% with terms, warranties/ options to be negotiated, also £1m of equity (already drawn). Strong demand for product – ~£80m of LOIs (diverse) with initial contracts signed and supply underway. $8bn of global opportunity today; projected $50bn by 2027, with high barriers to entry. Extensively licensed by UK Government – GMP, MHRA and Home Office Licencing; early mover in highly regulated market. Listed on London Stock Exchange @ £100m valuation (outperforming AIM All Share index by 33% since IPO)

Club Deal opportunity in Poland for professional investor, to close by YE 2023. Full occupancy yield 15% and IRR 30%+

A group of European investors is looking for one or more professional/ sophisticated co-investor(s) for a very attractive property transaction in Poland whereby an income producing asset (approx. 10% initial yield, 15% on full occupancy) can be bought at a very significant discount to replacement costs. In total there is a gap of approx. EUR 8-10m to be filled. This deal is urgent as the seller needs to get it done before YE, hence the attractive pricing. **STAK does not verify deal credentials you are responsible for your own due diligence, and opportunities are not accessible to retail investors**

£35m funding line available for purchase of Student Accommodation development opportunities in UK

Client is looking for opportunities in the UK to buy student accommodation sites or BTR schemes which are part built, distressed or in administration Large funding line up to £35m to deploy for Developers looking to exit existing finance arrangements that have come to an end

Co-investors sought for Biotech with commercialised infection prevention products for pre-listing funding

**Sophisticated investors only, enquiries via members please** Firm is the only company in the world to have registered a patent on a finished Hypochlorous Acid (HOCL) product, removing the need for alcohol-based sanitising products. They have created a formulation that not only has excellent shelf life but additionally maintains efficacy in the presence of serum (blood, saliva, dirt etc).
Up to £5m capital is currently being raised at a pre-money valuation of £58m (EIS shares and/or (ii) non-EIS convertible debt investment). This represents a 71% discount to the initial listing valuation of >£200m targeted by management at the Company’s planned IPO on the London Stock Exchange. To date >£14m invested in development of licensed technology into commercially viable products that meet an unmet public health need (funds raised via CLN) Two non-alcohol sanitising products already commercial, in active use in NHS. **Sophisticated/ Professional Investors ONLY** **Further details available within, verified members only**

EU regulated fund 10Yr record raised USD500m, 3x returns, requires 3yr bridge at 20% coupon but min 1.3x

The fund has a >10yr track record and has raised approx. USD 500m to-date with robust return prospects for investors (>2-3x). Invests in mining for rare earth minerals in EMEA Ideally bridge for 3yrs at 20% PIK interest but a min of 1.3x. Fund is exposed to mining but their commodities are sought after renewables commodities. Regulated fund with blue chip western investors (endowments, family offices etc.) Ideal investors are UHNW’s and Family Offices.

Invoice Discounter with £1.5bn financed to date, offering simple funding for SME's with 3 day turnaround

*Introducers Welcome* Invoice Discounter with £1.5bn financed to date, offering simple funding for SME's with 3 day turnaround. Selective invoice discounting allows you to forward fund invoices against quality counterparties. Lender has funded invoices for SME's against Pfizer, Apple, Aviva, BUPA and many others across 45 OECD countries. Credit policies will apply. $1.5bn, 120,000 invoices financed, across 1,800 debtors. $50k to $5m funding lines with no PG's, Liens, Debentures. Invoices financed via proprietary technology in GBP/ USD/ CAD/ EUR among others. Process is simple: load confirmed invoice, invoice verified by payer against bank account IN YOUR NAME, invoice paid to you and when payment received you are immediately paid invoice net of fees. This is non-recourse: invoice financier takes the risk.